解毒破瘀法抑制三阴性乳腺癌复发与转移的临床研究
Clinical Research on the Inhibition of Recurrence and Metastasis of Triple Negative Breast Cancer with the Method of Detoxification and Blood Stasis Dissipating
-
摘要: 目的 观察解毒破瘀法抑制三阴性乳腺癌(TNBC)复发与转移的临床疗效。方法 40例三阴性乳腺癌术后患者随机分为治疗组和对照组,各20例,对照组根据辨证施治随证加减,治疗者在辨证施治的同时加用解毒破瘀法,治疗3年,观察3年无病生存率(DFS)。结果 治疗组20例患者3年DFS为100%,对照组为75%,P<0.05。结论 解毒破瘀法能有效抑制三阴性乳腺癌复发及转移。Abstract: OBJECTIVE To observe the clinical efficacy of method of detoxification and blood stasis dissipating on the inhibition of recurrence and metastasis of triple negative breast cancer (TNBC). METHODS 40 cases of TNBC patients after operation were randomly divided into the control group and the treatment group, with 20 cases in each group. The control group was treated according to syndrome differentiation. The treatment group was treated with the method of detoxification and blood stasis dissipating beside the syndrome differentiation. Observe the disease free survival (DFS) of patients after 3-year treatment. RESULTS The DFS in the treatment group after 3-year treatment was 100%, while the control group 75% (P<0.05). CONCLUSION The method of detoxification and blood stasis dissipating can effectively inhibit the recurrence and metastasis of triple negative breast cancer.
-
[1] WHO. Globocan 2008:Estimated cancer as global health concern[J].Cancer incidence, mortality prevalence and disability-adjusted life years(DALYs) worldwise in 2008,2nd January 2013[OL]. http://globocan.iarc.fr/(22 February 2013, date last accessed). [2] Ossovskaya V, Wang Y, Budoff A, et al. Exploring molecular pathways of triple-negative breast cancer[J]. Genes Cancer, 2011, 2(9): 870-879. [3] 欧江华,蒋威华,倪多,等.新疆地区三阴性乳腺癌病理特征及预后分析[J].中国肿瘤临床,2011,38(18):1159-1162. [4] Ou JH, Jiang WH, Ni D, et al. Analysis on pathological feature and prognosis of triple negative breast cancer in Xinjiang aera[J]. Chin J Clin Oncol, 2011, 38(18): 1159-1162. [5] Baner KR, Brown M, Cress RD, et al. Descoiptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative,and HER2-negative phenotype a population-based study from the California cancer registry[J]. Cancer, 2007, 109(9): 1721-1728. [6] Tischkowitz M, Brunet JS, Bégin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7: 134. [7] AJCC癌症分期手册[M].严正,译.广州:中山大学肿瘤防治中心,2010. [8] AJCC. The Cancer Staging Manual[M]. Translated by Yan Z. Guangzhou: Sun Yat-Sen University Cancer Center, 2010. [9] 江泽飞,胡夕春, 王永胜,等.现代乳腺癌全程管理新理念和临床策略[M].上海:上海科技出版社,2013:365. [10] Jiang ZF, Hu XC, Wang YS, et al. Current New Concept and Clinical Strategy of Whole Management of Breast Cancer[M]. Shanghai: Shanghai scientific and technical publishers, 2013: 365. [11] 周际昌.实用肿瘤内科治疗学[M].北京:北京科学技术出版社,2012:32. [12] Zhou JC. Practical Medical Treatment of Cancer[M]. Beijing: Beijing science and technology press, 2012: 32. [13] 邵超,张晶晶,凌飞海,等.三阴性乳腺癌中核因子κB的表达与临床病理及预后[J].中华普通外科学,2015,9(1):29-33. [14] Shao C,Zhang JJ, Lin FH, et al. Clinical pathology, prognosis and the expression of nuclear factor κB of triple negative breast cancer[J]. Chin Gen Surg, 2015, 9(1): 29-33. [15] 张彦,李曼,赵璐,等.乳腺癌不同剂量表柔比星联合辅助化疗的疗效分析[J].中华肿瘤防治杂志,2014, 21(15):1168-1173. [16] Zhang Y, Li M, Zhao L, et al. Effect analysis of different doses of pharmorubicin combining adjuvant chemotherapy on breast cancer[J]. Chin J Cancer Prevent Treat, 2014, 21(15): 1168-1173. [17] 马文玥.卡铂联合紫杉醇治疗局部晚期三阴性乳腺癌的Ⅱ期临床研究[D].北京:北京协和医学院,2011. [18] Ma WY. Phase Ⅱ Study of Neoadjuvant Carboplatin Plus Paclitaxel for Locally Advanced Triple-negative Breast Cancer[D]. Beijing: Peking Union Medical College, 2011. [19] Liu Q. Triptolide and its expanding multiple pharmacological functions[J]. Int Immunopharmacol, 2011, 11(3): 377-383. [20] 张建国,苏永华.华蟾酥毒基药理作用及剂型研究进展[J].浙江中医药大学学报,2009, 33(4):608-610. [21] Zhang JG, Su YH. Research development of dosage form and pharmacological action of cinobufagin[J]. J Zhejiang Coll Tradit Chin Med, 2009, 33(4): 608-610. [22] Wu MB, Wu YL, Zhou J, et al. Structural characteristation of a water-soluble polysaccharide with high branches from the leaves of Taxus chinensis var mairei[J]. Food Chem,2009,113:1020-1024. [23] 刘敏,章永红,颜晓静,等.杉蟾藤成分复方诱导ER(+)人乳腺癌MCF-7细胞凋亡的实验研究[J].南京中医药大学学报,2014, 30(3):267-271. [24] Liu M, Zhang YH, Yan XJ, et al. Experimental research on apoptosis mechanism of ER(+) human breast cancer MCF-7 cells induced by the compound components of Shanchanteng[J]. J Nanjing Univ Tradit Chin Med, 2014, 30(3): 267-271.
点击查看大图
计量
- 文章访问数: 721
- HTML全文浏览量: 4
- PDF下载量: 711
- 被引次数: 0